Maite Bourlon: Happy to present the CheckMate9ER study at ASCO GU 2024
Maite Bourlon, the Head of the Urologic Oncology Clinic at Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Editorial Board Member of OncoDaily, shared on X (Twitter):
Happy to present the CheckMate9ER study at ASCO GU 2024
🔹 A P3 trial of cabo+nivolumab vs sunitinib in previously untreated advanced kidney cancer.
🔸At 55m folow-up efficacy of the combo is maintained in OS, PFS and ORR
🔹Thanks for the great team and support!”
Source: Maite Bourlon / X
Maria T Bourlon is an Associate Professor and Head of the Urologic Oncology Clinic at Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico. She is the Director of the Genitourinary Cancers Program at Universidad Nacional Autónoma de México. Dr. Bourlon is the chair-elect of the American Society of Clinical Oncology IDEA Steering Group and in 2023 received the prestigious ASCO CCF International Women Who Conquer Cancer (WWCC) Mentorship Award. She is on the Editorial Board of OncoDaily.
